Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases - Tung, N M; Im, S A; Senkus-Konefka, E (J Clin Oncol, 2018)
et al.